291 related articles for article (PubMed ID: 35963821)
41. Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study.
Savulescu C; Krizova P; Lepoutre A; Mereckiene J; Vestrheim DF; Ciruela P; Ordobas M; Guevara M; McDonald E; Morfeldt E; Kozakova J; Varon E; Cotter S; Winje BA; Munoz-Almagro C; Garcia L; Castilla J; Smith A; Henriques-Normark B; Celentano LP; Hanquet G;
Lancet Respir Med; 2017 Aug; 5(8):648-656. PubMed ID: 28359798
[TBL] [Abstract][Full Text] [Related]
42. Evolution of serotypes in bacteremic pneumococcal adult pneumonia in the period 2001-2014, after introduction of the pneumococcal conjugate vaccine in bizkaia (spain).
España PP; Uranga A; Ruiz LA; Quintana JM; Bilbao A; Aramburu A; Serrano L; Ayarza R; Martinez AP; Zalacain R
Vaccine; 2019 Jun; 37(29):3840-3848. PubMed ID: 31153692
[TBL] [Abstract][Full Text] [Related]
43. Exploring the evidence behind the comparable impact of the pneumococcal conjugate vaccines PHiD-CV and PCV13 on overall pneumococcal disease.
Izurieta P; Nieto Guevara J
Hum Vaccin Immunother; 2022 Dec; 18(1):1872341. PubMed ID: 33605846
[TBL] [Abstract][Full Text] [Related]
44. Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis.
Ta A; Kühne F; Laurenz M; von Eiff C; Warren S; Perdrizet J
Infect Dis Ther; 2024 Jun; 13(6):1333-1358. PubMed ID: 38733494
[TBL] [Abstract][Full Text] [Related]
45. Expanded Analysis of 20 Pneumococcal Serotypes Associated With Radiographically Confirmed Community-acquired Pneumonia in Hospitalized US Adults.
Isturiz R; Grant L; Gray S; Alexander-Parrish R; Jiang Q; Jodar L; Peyrani P; Ford KD; Pride MW; Self WH; Counselman F; Volturo G; Ostrosky-Zeichner L; Wunderink RG; Sherwin R; Overcash JS; File T; Ramirez J
Clin Infect Dis; 2021 Oct; 73(7):1216-1222. PubMed ID: 33982098
[TBL] [Abstract][Full Text] [Related]
46. Impact of the introduction of a 13-valent pneumococcal vaccine on pneumococcal serotypes in non-invasive isolates from 2007 to 2016 at a teaching hospital in Japan.
Suzuki S; Osato R; Wajima T; Hasebe T; Ishikawa H; Mitsumori H; Nakaminami H; Noguchi N
J Med Microbiol; 2019 Jun; 68(6):903-909. PubMed ID: 31090535
[TBL] [Abstract][Full Text] [Related]
47. Dynamic changes in clinical characteristics and serotype distribution of invasive pneumococcal disease among adults in Japan after introduction of the pediatric 13-valent pneumococcal conjugate vaccine in 2013-2019.
Tamura K; Chang B; Shimbashi R; Watanabe H; Tanabe Y; Kuronuma K; Oshima K; Maruyama T; Fujita J; Abe S; Kasahara K; Nishi J; Kubota T; Kinjo Y; Fujikura H; Fukusumi M; Shimada T; Sunagawa T; Suzuki M; Yamamoto Y; Oishi K;
Vaccine; 2022 May; 40(24):3338-3344. PubMed ID: 35489986
[TBL] [Abstract][Full Text] [Related]
48. Effectiveness of Pneumococcal Conjugate Vaccines Against Community-acquired Alveolar Pneumonia Attributable to Vaccine-serotype Streptococcus pneumoniae Among Children.
Lewnard JA; Givon-Lavi N; Dagan R
Clin Infect Dis; 2021 Oct; 73(7):e1423-e1433. PubMed ID: 33346348
[TBL] [Abstract][Full Text] [Related]
49. Pneumonia hospitalization after introduction of pneumococcal conjugate vaccine in Japan: Descriptive study using a nationwide claims database.
Yanai T; Yoshida S; Takeuchi M; Kawakami K
Vaccine; 2023 Jun; 41(29):4313-4318. PubMed ID: 37286407
[TBL] [Abstract][Full Text] [Related]
50. Clinical and Bacteriological Analysis of Pediatric Pneumococcal Meningitis after 13-Valent Pneumococcal Conjugate Vaccine Introduction in Japan.
Kurihara E; Takeshita K; Tanaka S; Takeuchi N; Ohkusu M; Hishiki H; Ishiwada N
Microbiol Spectr; 2022 Apr; 10(2):e0182221. PubMed ID: 35357224
[TBL] [Abstract][Full Text] [Related]
51. A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children.
Mungall BA; Hoet B; Nieto Guevara J; Soumahoro L
Expert Rev Vaccines; 2022 Feb; 21(2):201-214. PubMed ID: 34882050
[TBL] [Abstract][Full Text] [Related]
52. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ;
Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105
[TBL] [Abstract][Full Text] [Related]
53. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
[TBL] [Abstract][Full Text] [Related]
54. Secular trends (1990-2013) in serotypes and associated non-susceptibility of S. pneumoniae isolates causing invasive disease in the pre-/post-era of pneumococcal conjugate vaccines in Spanish regions without universal paediatric pneumococcal vaccination.
Fenoll A; Granizo JJ; Giménez MJ; Yuste J; Aguilar L
Vaccine; 2015 Oct; 33(42):5691-5699. PubMed ID: 26341563
[TBL] [Abstract][Full Text] [Related]
55. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
[TBL] [Abstract][Full Text] [Related]
56. Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years.
Essink B; Sabharwal C; Cannon K; Frenck R; Lal H; Xu X; Sundaraiyer V; Peng Y; Moyer L; Pride MW; Scully IL; Jansen KU; Gruber WC; Scott DA; Watson W
Clin Infect Dis; 2022 Aug; 75(3):390-398. PubMed ID: 34940806
[TBL] [Abstract][Full Text] [Related]
57. Pneumococcal Mastoiditis in Children Before and After the Introduction of Conjugate Pneumococcal Vaccines.
Koutouzis EI; Michos A; Koutouzi FI; Chatzichristou P; Parpounas K; Georgaki A; Theodoridou M; Tsakris A; Syriopoulou VP
Pediatr Infect Dis J; 2016 Mar; 35(3):292-6. PubMed ID: 26569193
[TBL] [Abstract][Full Text] [Related]
58. Can the success of pneumococcal conjugate vaccines for the prevention of pneumococcal diseases in children be extrapolated to adults?
Weil-Olivier C; Gaillat J
Vaccine; 2014 Apr; 32(18):2022-6. PubMed ID: 24565755
[TBL] [Abstract][Full Text] [Related]
59. Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden.
Galanis I; Lindstrand A; Darenberg J; Browall S; Nannapaneni P; Sjöström K; Morfeldt E; Naucler P; Blennow M; Örtqvist Å; Henriques-Normark B
Eur Respir J; 2016 Apr; 47(4):1208-18. PubMed ID: 26797033
[TBL] [Abstract][Full Text] [Related]
60. PCV13-vaccinated children still carrying PCV13 additional serotypes show similar carriage density to a control group of PCV7-vaccinated children.
Dagan R; Juergens C; Trammel J; Patterson S; Greenberg D; Givon-Lavi N; Porat N; Gruber WC; Scott DA
Vaccine; 2017 Feb; 35(6):945-950. PubMed ID: 28087146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
